Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history. [electronic resource]
- Leukemia Jan 2010
- 6-12 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
1476-5551
10.1038/leu.2009.193 doi
Antineoplastic Agents--therapeutic use Benzamides Dasatinib Drug Resistance, Neoplasm Fusion Proteins, bcr-abl--genetics Humans Imatinib Mesylate Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy Mutation Piperazines--adverse effects Protein Kinase Inhibitors--therapeutic use Pyrimidines--adverse effects Thiazoles--therapeutic use